搜索
Vyne Therapeutics Inc
VYNE添加自选
0.681USD
+0.030+4.66%
收盘 07/01, 16:00（美东）报价延迟15分钟
22.71M总市值
亏损市盈率 TTM
关于 Vyne Therapeutics Inc 公司
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Vyne Therapeutics Inc简介
公司代码VYNE
公司名称Vyne Therapeutics Inc
上市日期Jan 25, 2018
CEODomzalski (David)
员工数量13
证券类型Ordinary Share
年结日Jan 25
公司地址685 Route 202/206 N., Suite 301
城市BRIDGEWATER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编08807
电话18007757936
网址https://vynetherapeutics.com/
公司代码VYNE
上市日期Jan 25, 2018
CEODomzalski (David)
Vyne Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.86K
+25.14%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.57K
+0.61%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.86K
+25.14%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.57K
+0.61%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
常见问题
Vyne Therapeutics Inc的前五大股东是谁？
Vyne Therapeutics Inc 的前五大股东如下：Mr. Tyler Zeronda
有多少机构持有Vyne Therapeutics Inc(VYNE)的股份？
截至2026Q1，共有92家机构持有Vyne Therapeutics Inc的股份，合计持有的股份价值约为11.08M，占公司总股份的33.26%。与2025Q4相比，机构持股有所增加，增幅为-1672969.00。